Lentiviral Mediated ADA2 Gene Transfer Corrects the Defects Associated With Deficiency of Adenosine Deaminase Type 2

Ying Hong1*, Marina Casimir1, Benjamin C. Houghton1, Fang Zhang1, Barbara Jensen1, Ebun Omoyinmi1, Robert Torrance1, Charalampia Papadopoulou1, Michelle Cummins2, Marion Roderick3, Adrian J. Thrasher1, Paul A. Brogan1 and Despina Eleftheriou1,4

1 Infection, Immunity, Inflammation Department, University College London (UCL) Great Ormond Street Institute of Child Health, London, United Kingdom, 2 Paediatric Haematology, Bristol Royal Hospital for Children, Bristol, United Kingdom, 3 Paediatric Clinical Immunology, Bristol Royal Hospital for Children, Bristol, United Kingdom, 4 Versus Arthritis Centre for Adolescent Rheumatology, University College London (UCL), London, United Kingdom

Deﬁciency of adenosine deaminase type 2 (DADA2) is an autosomal recessive disease caused by bi-allelic loss-of-function mutations in ADA2. Treatment with anti-TNF is effective for the autoinflammatory and vasculitic components of the disease but does not correct marrow failure or immunodeﬁciency; and anti-drug antibodies cause loss of efﬁcacy over time. Allogeneic haematopoietic stem cell transplantation may be curative, but graft versus host disease remains a signiﬁcant concern. Autologous gene therapy would therefore be an attractive longer-term therapeutic option. We investigated whether lentiviral vector (LV)–mediated ADA2 gene correction could rescue the immunophenotype of DADA2 in primary immune cells derived from patients and in cell line models. Lentiviral transduction led to: i) restoration of ADA2 protein expression and enzymatic activity; (ii) amelioration of M1 macrophage cytokine production, IFN-γ and phosphorylated STAT1 expression in patient-derived macrophages; and (iii) amelioration of macrophage-mediated endothelial activation that drives the vasculitis of DADA2. We also successfully transduced human CD34+ haematopoietic stem progenitor cells (HSPC) derived from a DADA2 patient with pure red cell aplasia and observed restoration of ADA2 expression and enzymatic activity in CD34+HSPC, alongside recovery of stem-cell proliferative and colony forming unit capacity. These preclinical data now expand the evidence for the efﬁcacy of gene transfer strategies in DADA2, and strongly support clinical translation of a lentivirus-mediated gene therapy approach to treat DADA2.

Keywords: gene therapy, DADA2, stem cells, macrophages, anti-TNF

1 INTRODUCTION

Deficiency of adenosine deaminase type 2 (DADA2) is an autosomal recessive genetic disease with systemic inﬂammation and vasculitis, caused by loss of function mutations in ADA2 (1–3). ADA2 encodes the extracellular enzyme ADA2 (1–6). ADA2 is one of two isoforms of adenosine deaminase, the other being ADA1, deﬁciency of which causes severe combined immunodeﬁciency
donors is increasingly successful, it comes with significant risk and although transplantation using HLA-mismatched donors, however, poses a constraint for mortality, and long-term morbidity (13, 15). Autologous to incomplete immune cell reconstitution, higher risks of (13 HSCT have been undertaken in several DADA2 patients, with up to 10-years follow-up indicating favourable results (13–15). Limited availability of Human Leukocyte Antigen (HLA)-matched donors, however, poses a constraint for many; and although transplantation using HLA-mismatched donors is increasingly successful, it comes with significant risk including graft versus host disease and graft rejection, leading to incomplete immune cell reconstitution, higher risks of mortality, and long-term morbidity (13, 15). Autologous gene therapy would provide an attractive therapeutic option for DADA2 by genetically correcting patient stem cells through the use of viral vectors. A previous report by Zoccolillo and colleagues explored this approach in DADA2, demonstrating that lentiviral (LV)-mediated ADA2 gene transfer can restore ADA2 enzymatic activity in patient haematopoietic stem progenitor cells (HSPC) and corrects macrophage inflammatory activation (16). We now provide additional data evaluating the efficacy of another ADA2 encoding LV in support of this approach, for the future development of clinical studies. Importantly, we also show ex vivo that LV mediated ADA2 gene transfer: (i) restored ADA2 expression and enzymatic activity in CD34+HSPCs derived from a DADA2 patient with severe bone marrow involvement presenting as pure red cell aplasia (PRCA), resulting in the recovery of stem cell proliferative and colony forming unit capacity; (ii) ameliorated macrophage-mediated endothelial activation that drives the vasculitis of DADA2; and (iii) reduced IFN-γ and phosphorylated STAT1 expression in patient-derived macrophages, thus effectively targeting key pathogenic immune pathways of DADA2.

2 MATERIALS AND METHODS

2.1 Study Participants

This study was approved by the Bloomsbury Ethics Committee (no. 08H071382). We obtained written informed consent from all family members, age-appropriate consent, and adolescent healthy control subjects with additional local ethics approval (REC 11/LO/0330). The genotype, phenotype and treatments used for the patients recruited to the study are summarised in Table 1.

2.2 Methods

2.2.1 Vector Constructs

Human primary immune cell and THP-1 cell line transduction experiments were carried out by using a third-generation lentiviral vector on a pCCL backbone containing codon-optimized human ADA2 cDNA driven by the elongation factor 1α short (EFS) promoter, internal ribosomal entry site (IRES), and enhanced green fluorescent protein (eGFP), or eGFP alone (EFS-ADA2-eGFP, EFS-eGFP). Vectors were produced by transient transfection of HEK293T cells as previously described (17).

2.2.2 CRISPR-Cas9 ADA2 Knock-Out (KO) and ADA2 Mutant THP-1 Cell Line

THP-1 cells were transfected with CRISPR/Cas9 ADA2 KO plasmid (SantaCruz, USA) using Lipofectamine 2000. At 72 hours post transfection, GFP positive cells were sorted using MoFlo SDP flow cytometry, and a single cell was plated in each well of 96 well plates. Following 3 weeks of cell culturing, 2 clones (Clone 1 and Clone 2) were formed and transferred into T-25 for further expansion. Sanger sequencing of ADA2 (Exon 4 and Exon 5) showed deletions in both isolated clones. Western blotting confirmed the KO of ADA2 protein in both clones. The Q5 Site-Direct Mutagenesis kit (New England Biolab) was used to create single base substitutes on the vector pCCL-EFS-ADA2-eGFP. Primers were designed using the NEBasechanger web tool (http://nebasechanger.neb.com); sequences are available upon request. To generate mutant ADA2-G47R or ADA2-R169Q cells, ADA2-KO THP-1 cells were transduced with lentivirus encoding p.G47R or p.R169Q mutant ADA2.

2.2.3 Peripheral Blood Mononuclear Cell (PBMC) Isolation, Immune Cell Sorting and Monocyte-Derived Macrophage Cell Culture, Differentiation and Cell Transduction

PBMC were isolated from 15 mL of blood from patient and control subjects by using density gradient centrifugation (Lymphoprep; STEMCELL Technologies, Vancouver, British Columbia, Canada) cultured in RPMI 1640 with glutamine (Sigma-Aldrich, St Louis, Mo) supplemented with 10% FCS. PBMC (4 x 10^6) were plated, and after 2 hours, adherent monocytes were washed and cultured in the presence of 50 ng/mL macrophage colony-stimulating factor (PeproTech, Rocky
Clinical features
Testicular ischaemia,
Infantile neutropenia,
Hepatosplenomegaly,
Livedo racemosa.

ADA2 enzyme activity
(serum/ cellular) (U/L)

TABLE 1 | Demographics, clinical features, genotype and treatment of patients with deficiency in adenosine deaminase type 2 (DADA2).

| Patients | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
|----------|---|---|---|---|---|---|---|---|
| Age      | 9.1 | 14.5 | 12.3 | 16.3 | 11.9 | 13 | 6.9 | 0.4 |
| Sex      | M | F | M | F | M | P | M | P |
| Genotype | p.G47R/ | p.G47R/ | p.G47R/ | p.G47R/ | p.M1T/p.R49Gfs* | p.P251L/ | p.P251L/ | p.Y227C/ |
| ADA2 enzyme activity | 2.1 | 0 | 0 | 1.6 | 0 | 0 | 0 | 0 |

| Immunoglobulins | | | | | | | | |
|-----------------|---|---|---|---|---|---|---|---|
| IgG (RR 5.40-16.10) G/L | 7.40 | 11.90 | 11.50 | 3.79 | 10.20 | 14.40 | 9.70 | 6.41 |
| IgA (RR 0.70-2.50) G/L | 1.44 | 2.70 | 3.78 | 0.73 | 1.24 | 1.94 | 0.46 | 0.33 |
| IgM (RR 0.50-1.80) G/L | 0.40 | 1.20 | 0.96 | 0.05 | 0.42 | 1.6 | 0.92 | 0.27 |
| Full blood count | | | | | | | | |
| Hgb (RR 115-155 G/L) | 120-140 | 126-141 | 127-134 | 104-157 | 129-138 | 133 | 103-124 | 46 |
| White cells (RR 4.5-13.5x10^9/L) | 206-228 | 160-258 | 252-670x10^9 | 9 | 284-330x10^9 | 260 x10^9 | 314-528x10^9 | 9 |
| Neutrophils (RR 1.5-8 x10^9/L) | 3.35-5.28 x10^9 | 7.7-11.21 | 3.02-16.10 x10^9 | 9 | 4.87-6.50x10^9 | 8.23x10^9 | 5.23-7.18x10^9 | 9 |
| Lymphocytes (RR1.5-5x10^9/L) | 4.40-5.25 | 2.13-4.88 | 0.57-1.86 x10^9 | 9 | 2.28-3.21 x10^9 | 3.58 x10^9 | 1.39-2.94x10^9 | 9 |
| Erythrocyte sedimentation rate (RR< 15 mm/h) | 5-18 | 5-14 | 5-16 | 5-40 | 1-5 | 20 | 5-55 | Not available |
| C-reactive protein (RR< 5 mg/L) | <5 | <5 | <5 | 5-80 | <5 | <5 | <5 | Not available |

Clinical features
Testicular ischaemia,
Infantile neutropenia,
Hepatosplenomegaly,
Livedo racemosa.

Treatment
Adalimumab
Adalimumab
Adalimumab
Adalimumab
Adalimumab
Adalimumab
Adalimumab
Etanercept

Prednisolone was given at 2 mg/kg/day. Reference range for serum ADA2 enzyme activity is 5-18 U/L for healthy controls. Reference range for cellular ADA2 enzyme activity is 5-18 U/L for healthy control cells. For laboratory assessments where more than one result was available, range of lowest to highest value observed is presented.

Hill, NJ) to differentiate them to macrophages. At day 3 after transduction, cells were harvested and analysed by flow cytometry (FACScalibre; BD, San Jose, Calif) to establish transduction efficiency. PBMC were sorted with fluorescence-activated cell sorting (FACS) from healthy donor blood by using canonical cell population surface markers: B-cell CD19+ (clone HIB19; BioLegend, San Diego, Calif) and T-cell CD3+ (clone RPA-T8; BD Biosciences), NK cell CD56+ (clone RM4-5; BioLegend), monocyte CD14+ (clone M5E2; BioLegend). Granulocytes and red cells were pelleted at the bottom of the tube after the density gradient centrifugation of PBMC isolation. Granulocytes were obtained after red cell lysis using water.

CRISPR/Cas9 THP-1 ADA2 KO THP-1 cells were differentiated into macrophages following treatment for 24 hours with 100nM phorbol 12-myristate 13-acetate (PMA, Sigma). PMA-pretreated THP-1 cells and patient monocyte derived macrophages (MDM) were polarized into M1 macrophages following 24 hours with 100ng/ml LPS/20ng/ml INF-γ stimulation for 6 hours. Pro-inflammatory cytokine production was assessed in cultured cells or culture supernatants (see detailed methodology below).

2.2.4 CD34+Haematopoietic Stem Progenitor Cells (HSPC) Isolation, Transduction Macrophage Differentiation and Colony Forming Unit (CFU) Assay
CD34+HSPC were isolated from mobilized peripheral blood (for healthy donor cells) and bone marrow aspirate (for a patient with DADA2) by magnetic separation following the manufacturer’s protocol (Miltenyi Biotec, UK). CD34+ cells were seeded in growth medium (X-VIVO-15 + 1% human serum albumin, 20 ng/ml IL-3, 300 ng/ml stem cell factor [SCF], 300 ng/ml fms-like tyrosine kinase 3 ligand [FLT3L], and 100 ng/ml thrombopoietin [TPO]; Peprotech, UK) at a density of 0.5 x 10^6 cells/ml and pre-
stimulated overnight. Cells were transduced with lentiviral vector at MOI 50 in the presence of 4 μg/ml protamine sulfate for 16-18 hrs. After transduction, cells were maintained in liquid culture in the growth medium for cell proliferation and viral copy number (VCN) assay or grown as progenitors in semi-solid Methocult medium (STEMCELL) for 2 weeks. Cells were plated in MethoCult™ H4435 Enriched medium (StemCell Technologies) as per manufacturer’s instruction, using a density of 250 cells in a total volume of 1.1 mL per well of a 6-well plate. CFUs were enumerated by manual counting on day 14 post-plating, discriminating BFU-E (burst forming units-erythroid), CFU-GM (colony forming units granulocyte-macrophages) and CFU-GEMM (colony forming units granulocyte, monocyte, megakaryocyte).

After 4 days of transduction, CD34+ HSPC were seeded at a density of 40,000 cells per cm² in IMDM (ThermoFisher Scientific) supplemented with 25 ng/ml SCF, 30 ng/ml FLT3-ligand, 30 ng/ml IL-3, 30 ng/ml M-CSF, 10% FCS at 37°C/25% CO2. After 7 days in culture, cells were isolated for CD14+ monocytes using CD14+ Microbead kit (Miltenyi Biotec) according to the manufacturer’s instruction. Purified CD14+ monocytes were cultured in 24-well plates for a further 7 days in macrophage differentiation medium (IMDM supplemented with 50ng/ml M-CSF, 10% FCS and 1% PSF) to detect ADA2 protein expression and enzyme activity. Pro-inflammatory cytokine production was assessed in culture supernatants (see detailed methodology below).

### 2.2.5 Viral Copy Number (VCN)

Cells were harvested on day 14 post-transduction. Genomic DNA was extracted using the DNeasy Blood and Tissue Kit (Qiagen) as per manufacturer’s instruction. VCN were determined by TaqMan-based quantitative real-time PCR using primers and probes specific to the WPRE sequence of the vector (WPRE_FW 5'- TGGATTCTGGCCGGGA -3', PRE_RV 5'- GAAGGAAAGTCCGGTGGATT -3', PRE_probe 5'FAM-CTTCTGCTACGTCCCTCCGCT-3'TAMRA) and to the human albumin(ALB) reference gene (hALB_FW 5'- GCTGCTATCTCTTGTGGGCTGT-3', hALB_RV 5'- CCTGTCATGCCCACACAAATCTCTCC-TAMRA-3'). PCR reactions were carried out on a CFX96 Touch Real-Time System (Bio-Rad, Watford, UK) with Absolute QPCR ROX Mix (Thermo Fisher Scientific) and the following PCR program: 15 mins at 95°C, followed by 40 cycles of 15 secs at 95°C/30sec at 60°C/1 min at 72°C. A standard plasmid carrying the WPRE and human albumin target sequences served for absolute quantification of the mean VCN per cell.

### 2.2.6 Western Blotting

Cells were lysed in RIPA buffer (Thermo Fisher Scientific, Waltham, Mass) with 1% proteinase inhibitors (Roche Diagnostics). Lysates were boiled in the presence of 2 X Laemmli Buffer. Protein concentrations were measured using Pierce BCA Protein Assay (Thermo Fisher Scientific, UK). A total of 20 μg total protein was subjected to SDS-PAGE analysis and electro transferred onto polyvinylidene difluoride membranes (Millipore, Temecula, Calif). Membranes were blocked with milk, probed with primary and secondary antibodies, and visualized with the enhanced chemiluminescence detection system (Amersham Pharmacia Biotech, Little Chalfont, United Kingdom). The following antibodies were used: ADA2 (ab154619, Abcam), ACTN (MAB 1501R; Merck Millipore, Burlington, Mass), Goat anti-Rabbit IgG, HRP (ThermoFisher) and Rabbit anti-mouse IgG, HRP (ThermoFisher).

### 2.2.7 ADA2 Enzyme Activity

An ADA assay kit was used to quantify serum ADA2 enzyme activity, according to the instructions of the manufacturer (Diazyme). ADA2 activity in cell culture supernatants of PMA-primed THP-1, monocyte- or CD34+ cells-derived macrophages was measured using a modified, previously described automated spectrophotometric assay (18). The assay quantifies the adenosine-dependent generation of ammonia by coupling to the Glutamic Dehydrogenase (GDH)-catalyzed reaction of NH3 with α-ketoglutarate in the presence of NADH. ADA2 activity is distinguished from total ADA with the use of the selective inhibitor of ADA1, 100 nM EHNA (erythro-9-Amino-β-hexyl-α-methyl-9H-purine-9-ethano hydrochloride). The kinetics of each reaction were analyzed using an Optima Microplate Reader (BMG Labtech, UK). Serum levels of ADA2 activity ranged from 0-18 U/L (healthy control range 5-18 U/L); and in cell cultures from 0-13.9 U/L (healthy control range 4.54-13.9 U/L).

### 2.2.8 Flow Cytometric Detection of ADA2 Expression

Cells were harvested, washed, and centrifuged for 5 min at 300g. Cell surface staining was performed first in sterile-filtered FACS staining buffer composed of PBS supplemented with 0.5% BSA and 2 mM EDTA (BD, UK) with the appropriate amount of a fluorochrome-conjugated monoclonal antibody specific for a cell surface antigen such as CD3, CD14, CD19, CD56, CD68 or CD163 (30 mins, 4°C). After washing, cells were fixed and permeabilised with Cytofix/Cytoperm kit (BD Biosciences Pharmingen, Oxford, UK). Nonspecific binding was prevented by a 10 min blocking step with FcR blocking reagent, human (Miltenyi Biotec, UK) prior to incubating the cells for 60 mins on ice with PE-conjugated anti-ADA2 (Biorbyt, Cambridge, UK, 1:200). Stained cells were analyzed on the BD LSRII flow cytometer (BD Biosciences, Oxford, UK) using BD FACSDivas software, and data were analyzed using FlowJo software (TreeStar, Ashland, USA).

### 2.2.9 Quantitative Real-Time RT-PCR

We used TRizol™ reagent (Thermo Fisher) for RNA isolation from PBMC and sorted immune cells. The RNA concentration was assessed with a Nanodrop (Fluorostar Omega; Labtech, Orternberg, Germany). Total RNA was retrotranscribed to cDNA by using the Reverse Transcription kit (Applied Biosystems). We performed quantitative PCR analysis using the iTaq Universal SYBR Green Supermix (172-5121; Bio-Rad Laboratories, Hercules, Calif). The relative abundance of ADA2 transcripts in sorted immune cells was normalized to the expression level of Hypoxanthine Phosphoribosyltransferase 1 (HPRT1) assessed by using Bio-Rad CFX Maestro software.
2.2.10 Cytokine Assay
Cytokine levels were measured in the supernatants of monocyte-derived or CD34+ cell-derived macrophages and THP-1 cells using a Mesoscale Discovery multiplex kit (Mesoscale Diagnostics, Rockville, Md), according to the manufacturer’s instructions.

2.2.11 FACS Analysis of CD62E Expression in Endothelial Cells
Human umbilical vein endothelial cells (HUVEC) (Lonza) were cultured in EBM-2 supplemented with 2% Fetal Calf Serum (FCS), Growth factors as supplied by the manufacturer at 37°C under 5% CO2 in a humidified incubator. The 80% confluent HUVECs (passages 2 to 5) were used for most experiments. For CD62e expression assay, HUVECs were incubated with culture supernatants from MDM for 6 hours, surface expression of E-selectin (CD62e) on HUVECs was measured by flow cytometry as previously described (19).

2.2.12 STAT-1 Phosphorylation Assay
Monocyte derived macrophages (MDM) were treated with 100 U/ml IFNα for 30 min or examined untreated. Cells were fixed using BD Cell Fix Buffer (10 min at 37°C) and then permeabilized using BD PermIII Buffer (30min at 4°C). Cells were stained with BV421-anti-STAT1 pY701 (BD Bioscience, cat: 562985, 1:50) and cell surface markers APC-CD68 (Miltenyi Biotec, cat: 160-109-462, REA613, 1:30). Flow cytometric analysis was performed on a BD LSRII flow cytometer. Results were analyzed using FlowJo v10.4.2.

2.3 Statistical Analysis
All data were assembled and analyzed using GraphPad Prism software version 9. Results were expressed as mean and standard error of the mean, or median and range. ANOVA and T-test were used for group comparisons. P values of less than 0.05 were considered significant.

3 RESULTS
3.1 Lentivirus Mediated Transduction Efficiently Delivers ADA2 Expression and Enzymatic Activity in Human CD34+ Cells With No Detrimental Effect on Their Viability or Colony Forming Capacity
We first demonstrated the normal physiological pattern of ADA2 gene expression in FACs sorted leucocytes, which was highest in CD14+ monocytes; but also present in NK cells; T (CD3+); and B (CD19+) lymphocytes (Figure 1A). We therefore chose the ubiquitous promoter EFS (elongation factor 1α short) previously used in clinical trials for SCID (7) to generate self-inactivating lentiviral vectors containing a codon-optimized human ADA2 cDNA and Enhanced Green Fluorescent Protein (GFP), or GFP alone as a negative control vector (EFS-GFP). A schematic representation of the lentivirus construct design used in this study is shown in Figure 1B.

Using this vector, we evaluated the efficacy and toxicity of gene transfer following ex vivo transduction of CD34+ HSPC isolated from mobilized peripheral blood of 3 healthy donors. Transduction of these cells (VCN=2.91 ± 1.58) with EFS-ADA2-GFP increased the cellular expression of ADA2 and increased ADA2 enzyme activity in cell culture supernatant as shown in Figure 1C. In addition, there was no detrimental effect on the stem cell viability and ability of these cells to proliferate (Figure 1D) or their colony forming capacity across all myeloid and erythroid lineages, (Figure 1E).

3.2 Lentivirus Mediated Transduction Restores ADA2 Protein Expression, Enzyme Activity and Rescues Immunophenotype of CD34+HSPC From a Single Patient With Severe DADA2 and Pure Red Cell Aplasia
Next, we investigated the ability of lentiviral-ADA2 gene transfer to restore ADA2 protein expression and enzymatic activity in CD34+HSPC derived from a 3-month-old severe DADA2 patient with bone marrow involvement presenting with Pure Red-Cell Aplasia (PRCA) (genotype ADA2 p.G47W/p.G47W; see Table 1 for clinical characteristics). Transduction efficiency (GFP expression on day 7) was 36.8% for patient cells with VCN of 0.45 at day 14 post transduction compared to 36 ± 6.0% efficiency and VCN=2.91 ± 1.58 for control cells. We observed that EFS-ADA2-GFP-transduction of patient CD34+HSPC improved their ability to proliferate and to form colony-forming units across all myeloid and erythroid lineages, while there were no changes observed in untransduced (UT) cells treated only with EFS-GFP, or in healthy control CD34+HSPC (Figures 2A, B). EFS-ADA2-GFP transduction also improved the expression of ADA2 protein in CD34+HSPC as shown in Figure 2C and also improved the levels of ADA2 enzyme activity detected in the supernatant of macrophages derived from these cells (Figure 2D). There was also a reduction of proinflammatory cytokine (TNF-α, IL-6, and IFN-γ) release in culture supernatants from macrophages derived from EFS-GFP-ADA2 transduced patient CD34+HSPC compared to EFS-GFP alone treated cells, (Figure 2E). These results demonstrated that lentiviral-mediated transduction of CD34+HSPC derived from a patient with DADA2-associated marrow failure led to recovery of ADA2 protein expression and enzymatic activity, restored the colony-forming capacity of these stem cells, and ameliorated the autoinflammatory phenotype.

3.3 Lentivirus Mediated Transduction Restores ADA2 Protein Expression, Enzyme Activity and Rescues Immunophenotype in Monocyte Derived Macrophages From DADA2 Patients
We next examined whether LV transduction rescued the enzymatic activity and immunophenotype of monocyte-derived macrophages from DADA2 patients. Using this vector, we evaluated the efficiency and toxicity of gene transfer following ex vivo transduction of CD34+ HSPC isolated from mobilized peripheral blood of 3 healthy donors. Transduction of these cells (VCN=2.91 ± 1.58) with EFS-ADA2-GFP increased the cellular expression of ADA2 and increased ADA2 enzyme activity in cell culture supernatant as shown in Figure 1C. In addition, there was no detrimental effect on the stem cell viability and ability of these cells to proliferate (Figure 1D) or their colony forming capacity across all myeloid and erythroid lineages, (Figure 1E).
efficiency determined by using GFP expression; and VCN=4.6 ± 1.6 at day 7) and analyzed to determine the expression of ADA2 protein and enzyme activity. A representative flow cytometry histogram plot of ADA2 protein expression as assessed by flow cytometry is shown in Figure 3A. We observed increased ADA2 protein expression in transduced cells compared to EFS-GFP treated cells, p=0.04 (Figure 3B).

Similarly, there was an increase in ADA2 enzyme activity detected in the cell culture supernatant of EFS-GFP-ADA2 treated cells compared to EFS-GFP alone treated cells (p=0.03) and healthy control cells (Figure 3C). In addition, transduction with the EFS-ADA2-GFP vector reduced TNF-α release compared to treatment with EFS-GFP alone, p=0.04 (Figures 3D). Figure 3E demonstrates the changes in levels of released TNF-α observed for each individual sample assessed post EFS-GFP-ADA2 transduction.

In view of recent reports suggesting upregulation of type II interferon and STAT1 hyperactivation in monocytes of patients with DADA2 (20), we next investigated the effect of LV-mediated ADA2 gene transfer on these pathways. EFS-ADA2-GFP transduction of MDM derived from patients with DADA2 led to amelioration in IFN-γ release in culture supernatants of resting unstimulated cells compared to levels released in EFS-GFP-treated cells (p=0.03); and downregulation of phosphorylated STAT1 pY701 expression in IFN-stimulated cells, p=0.05 (Figures 3F, G).

3.4 Lentivirus Mediated Transduction Prevents Endothelial Activation Induced by Macrophages From DADA2 Patients

Endothelial activation via cytokine release from macrophages is an important driver of vasculitis in DADA2 (1, 2, 21). To examine the effects of LV-mediated ADA2 gene transfer on MDM-mediated endothelial activation, culture supernatants from MDM from DADA2 patients were co-incubated with human umbilical vein endothelial cells (HUVEC). CD-62E expression on HUVEC was then used to assess endothelial activation (22). There was a significant reduction in CD62E expression on HUVEC incubated with culture supernatants from EFS-GFP-ADA2 transduced MDM compared to EFS-GFP treated MDM, p=0.04 (Figure 3H).
3.5 ADA2 Protein Expression, Enzyme Activity and Macrophage Responses in ADA2 Deficient Cell Line Models

Lastly, we also confirmed in a cell line model that the amplified inflammatory macrophage responses seen in DADA2 are a cell-intrinsic consequence of the loss of ADA2 function and are rescued following restoration of ADA2 function. We developed a CRISPR/Cas9 ADA2 knock-out (KO) THP-1 cell line model and confirmed absent ADA2 protein expression and ADA2 enzyme activity in these cells compared to wild-type (WT) THP-1 cells (Figures 4A–C).

M1 macrophages derived from ADA2 KO THP1 cells exhibited significant upregulation of TNF secretion compared to M1 macrophages derived from WT cells (Figure 4D). This was a similar pattern of upregulated TNF secretion as that observed in M1 macrophages derived from patients with DADA2 compared with age matched healthy controls (Figure 3D), confirming that our CRISPR/Cas9 THP-1 cell line model closely recapitulated the immunophenotype observed in primary immune cells from patients with DADA2 (1, 2). We next transduced ADA2-KO THP-1 cells with a LV encoding wild-type ADA2 (WT-ADA2), or with ADA2 p.G47R or p.R169Q mutants that are commonly seen in DADA2 patients. As expected, this resulted in detectable ADA2 protein expression with EFS-WT ADA2 and EFS-G47R ADA2, EFS-R169Q ADA2 vectors (Figures 4A, B); but we only observed restoration of ADA2 enzyme activity in the supernatants of cells transduced with EFS-WT ADA2, compared to no recovery of ADA2 activity when cells were treated with EFS-GFP; or when the EFS-G47R ADA2, EFS-R169Q ADA2 vectors were used (Figure 4C). In addition, we observed reduction of TNFα release in EFS-GFP-ADA2 vector transduced M1 macrophages; but not following treatment with EFS–GFP, EFS-G47R ADA2, EFS-R169Q ADA2 cells (Figure 4D).
Treatment options for those with DADA2 associated immunodeficiency or marrow aplasia are extremely limited, and largely dependent on allogeneic-HSCT (15, 23). Similarly, treatment for those with autoinflammation and vasculitis who escape efficacy from anti-TNF (e.g. by development of anti-drug antibodies) have a guarded prognosis, with significant risk of stroke or death (24, 25). Autologous gene therapy would therefore provide an attractive and obvious alternative therapeutic option. We now provide additional data that significantly adds to the only other pre-clinical study (16) exploring this approach. Our results provide further proof of concept for the efficacy of gene transfer strategies for the treatment of DADA2 using LV and the EFS promoter, which rescued stem cells and their progeny from a patient with ADA2-associated red cell aplasia. We also demonstrated the beneficial effects of gene transfer on macrophage-mediated endothelial activation and IFN-driven autoinflammation. These observations, combined with those of others, move us ever closer to human trials of LV gene therapy for DADA2 (16).
We showed that LV transduction leads to restoration of ADA2 protein expression and enzymatic activity; and amelioration of M1 macrophage cytokine production, in line with a previous report (16). Our additional experiments in an ADA2-deficient THP-1 cell line confirmed that correction of the macrophage auto-inflammatory phenotype required recovery of functional ADA2 activity. It would be interesting to replicate the results of our experiments by using other monocytic cell line sources. We also observed that LV transduction led to reduction of IFN-γ and phosphorylated STAT1 expression in patient-derived macrophages; and ameliorated macrophage mediated endothelial activation, considered to be the main driver of vasculitis in DADA2. Our results do not preclude the possibility that other pathways may also be rescued by LV gene transfer in DADA2 patients such as NF-kB, and type-I IFN responses (11). These need to be further explored in future studies. Any potential safety effects of ADA2 protein overexpression will also need to be fully established in vivo, a step significantly hampered by lack of a suitable murine model of DADA2 (26). Further studies now also need to explore the effects of ADA2 expression on CD34+HSPC subset distribution and senescence for patient derived HSPC and CD34+HPSC edited to express the G47R and R169Q ADA2 mutants.

Optimization of transgene expression is paramount for successful gene modification of primary cells for clinical applications, and careful selection of the viral vector construct is a critical part of this process (27). EFS is a promoter that has been used successfully in previous clinical trials (28). It is a cellular-derived enhancer/promoter with decreased cross-activation of nearby promoters, therefore minimizing the risk of genotoxicity (28). In addition, EFS can target all HSPC and not only myeloid cells (7, 28). We designed viral constructs under this promoter since although ADA2 is preferentially expressed in myeloid cells, it is also expressed in lymphocytes albeit at lower levels. Emerging clinical studies suggest that the immunophenotype of DADA2 may also be driven by intrinsic defects of B and T cells (24, 29–32). Therefore, human gene transfer for DADA2 should target lymphocytic compartments as
well as myeloid to ensure complete resolution of the clinical phenotype (4, 6, 24, 29). In addition to robust expression in stem cells, the safety and efficacy profile of the EFS promoter that we have chosen is well established through several previous clinical trials. Further studies may also need to compare vectors carrying either the EFS or PGK promoter and examine their stability and transduction efficiency in stem cells derived from patients with DADA2. Alternative promoters may also need to be explored in future studies for clinical translation (33).

LV gene transfer may not be the only possibility for DADA2 in the future. Precise targeting by means of gene editing has recently emerged as an alternative technology to overcome the limitations of conventional gene therapy (34–37). Engineered endonucleases that introduce double-strand breaks at specific sequences in the genome offer much more control compared with viral vector integration (34–36). Such site-specific correction of the disease-causing mutant DNA in situ potentially offers a more physiological regulated expression of the corrected gene in edited cells (34–36). Such platforms are being actively pursued by our group for DADA2 in parallel to our LV program. Major challenges to these alternative approaches remain to be solved, such as: optimising the delivery of the editing machinery; achieving sustained targeted integration; and ensuring restoration of therapeutic relevant levels of protein expression. Preliminary proof of concept studies have recently overcome some of these hurdles by developing a highly specific and efficient CRISPR/Cas9 coupled to an adeno-associated virus (AAV) 6 editing system to insert a codon-optimized cDNA in HSPC, thus setting the groundwork for alternative, yet highly efficient, safe, and precise treatments for genetic diseases such as DADA2 (34). We acknowledge that these more accurate gene editing approaches still require further study before they translate into clinical applications in humans. In view of the urgent clinical need and in light of the extensive safety and efficacy data that already exist for LV gene therapies, we have chosen to focus our efforts on delivering LV mediated gene transfer therapy for DADA2 in the first instance.

Whilst the clinical indications for gene therapy for DADA2 remain to be established, the first obvious indications might include patients with marrow failure, immune deficiency, or refractory vasculitis without any suitable donor for allogeneic HSCT. Secondly, DADA2 patients who develop anti-drug antibodies to anti-TNF (e.g., patient 6, Table 1), would be another indication, a scenario we envisage encountering more frequently as more patients receive anti-TNF over several years. Thus, we suggest that the clinical need for gene therapy is growing and highlight the urgency for rapid clinical translation of a LV-mediated cell gene therapy to human trials. Key issues to address in future studies along this translational pathway include: (i) examining the ability of HSPC to engraft in vivo in the context of ongoing inflammation and active vasculitis; (ii) identifying the optimal target recovery range of ADA2 enzyme activity given that carriers with reduced enzymatic activity are asymptomatic, and therefore lower than normal levels may be therapeutically sufficient; (iii) establishing the optimal conditioning regimen required during gene therapy, aiming for reduced intensity conditioning with limited toxicity.

In conclusion, the preclinical data presented herein provide further proof of concept for the efficacy of gene transfer strategies for the treatment of DADA2 and strengthen the foundation for clinical translation of a LV-mediated cell gene therapy approach to treat patients with this disease.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

This study was approved by the Bloomsbury Ethics Committee (no. 08H071382). We obtained written informed consent from all family members, age-appropriate consent, and adolescent healthy control subjects with additional local ethics approval (REC 11/LO/0330). Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.

AUTHOR CONTRIBUTIONS

DE, PB, and YH conceived the study, designed experiments, collected and analysed data and drafted the manuscript. All other authors obtained and analysed data and revised the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This work was funded by Versus Arthritis (grant 21791 and 21593), GOSH Children’s Charity (grant V0218). DE, AT, and PB acknowledge support from Great Ormond Street Hospital Children’s Charity and NIHR Great Ormond Street Hospital Biomedical Research Centre. BH was supported by Action Medical Research (Grant GN2814). AT and FZ were supported by Welcome Trust (grant 217112/Z/19/Z).

ACKNOWLEDGMENTS

We acknowledge all patients and families who participated in this study.
REFERENCES

1. Zhou Q, Yang D, Ombrello AK, Zavialov AV, Toro C, Zavialov AV, et al. Early-Onset Stroke and Vasculopathy Associated With Mutations in ADA2. *N Engl J Med* (2014) 370(10):911–20. doi: 10.1056/NEJMoA1307361

2. Navon Elkan P, Pierce SR, Segel R, Walsh T, Barzadi J, Padeh S, et al. Mutant Adenosine Deaminase 2 in a Polyarteritis Nodosum Vasculopathy. *N Engl J Med* (2014) 370(10):921–31. doi: 10.1056/NEJMoA1307362

3. Nanthapisal S, Murphy C, Omoiyinmi E, Hong Y, Standing A, Berg S, et al. Variable Clinical Phenotypes and Relation of Interferon Signature With Disease Activity in ADA2 Deficiency. *J Rheumatol* (2019) 46(5):523–6. doi: 10.3899/jrheum.180045

4. Hashem H. Hematopoietic Cell Transplantation Cures Adenosine Deaminase 2 Deficiency: Report on 30 Patients. *J Clin Immunol* (2021) 41(7):1633–47. doi: 10.1007/s10875-021-01098-0

5. Lee PY, Kellner ES, Huang Y, Furutani E, Huang Z, Bainter W, et al. Genotype and Functional Correlates of Disease Phenotype in Deficiency of Adenosine Deaminase 2 (DADA2). *J Allergy Clin Immunol* (2020) 145(6):1664–72.e10. doi: 10.1016/j.jaci.2019.12.908

6. Booth C, Romano R, Roncarolo MG, Thrasher AJ. Gene Therapy for Primary Immunodeficiency. *Hum Mol Genet* (2019) 28(R1):R15–23. doi: 10.1093/hmg/ddz170

7. Ombrello AK, Qin J, Hoffmann PM, Kumar P, Stone D, Jones A, et al. Treatment Strategies for Deficiency of Adenosine Deaminase 2. *N Engl J Med* (2019) 380(16):1582–4. doi: 10.1056/NEJMci1801927

8. Lee PY, Kellner ES, Huang Y, Furutani E, Huang Z, Bainter W, et al. Genotype and Functional Correlates of Disease Phenotype in Deficiency of Adenosine Deaminase 2 (DADA2). *J Allergy Clin Immunol* (2020) 145(6):1664–72.e10. doi: 10.1016/j.jaci.2019.12.908

9. Zavialov AV, EnгрÖstrÖm Å. Human ADA2 Belongs to a New Family of Growth Factors With Adenosine Deaminase Activity. *Biochem J* (2005) 391(1):51–7. doi: 10.1042/BJ20050683

10. Zavialov AV, Gracia E, Glaiuchenhaus N, Franco R, Zavialov AV, Lauvau G. Human Adenosine Deaminase 2 Induces Differentiation of Monocytes Into Macrophages and Stimulates Proliferation of T Helper Cells and Macrophages. *J Leukoc Biol* (2010) 88(2):279–90. doi: 10.1189/jlb.1109764

11. Deucht NT, Yang D, Lee PY, Yu X, Moura NS, Schnappauf O, et al. TNF Inhibition in Vasculitis Management in Adenosine Deaminase 2 Deficiency (DADA2). *J Allergy Clin Immunol* (2021) S0091-6749(21):01693-6. doi: 10.1016/j.jaci.2021.07.097

12. Coarsi R, Penco F, Grossi A, Penco F, Caorsi R, Palmisani E, Terranova P, et al. Case Report: Deficiency of Adenosine Deaminase 2 Presenting With Overlapping Features of Autoimmune Lymphoproliferative Syndrome and Bone Marrow Failure. *Front Immunol* (2021) 12:4222. doi: 10.3389/fimmu.2021.754029

13. Corrêa S, Cotrim J, Costa C, Sampaio E, Filho A, et al. Study of the Distribution of Leucocytes in Patients With ADA2 Deficiency. *Arthritis Rheumatol* (2021) 73(9):2456–62. doi: 10.1002/art.41837

14. Hashem H. Hematopoietic Cell Transplantation Cures Adenosine Deaminase 2 Deficiency: Report on 30 Patients. *J Clin Immunol* (2021) 41(7):1633–47. doi: 10.1007/s10875-021-01098-0

15. Schepp J, Proietti M, Brede N, Bucht a, Hübscher K, Rojas Restrepo J, et al. Screening of 181 Patients With Antibody Deficiency for Deficiency of Adenosine Deaminase 2 Sheds New Light on the Disease in Adulthood: ADA2 IN PATIENTS WITH ANTIBODY DEFICIENCY. *Arthritis Rheumatol* (2017) 69(8):1689–700. doi: 10.1002/art.40147

16. Poletti V, Mavilio F. Designing Lentiviral Vectors for Gene Therapy of Genetic Diseases. *Viruses* (2011) 13(8):1532. doi: 10.3390/v13081526

17. Poletti V, Chirrier S, Corre G, Gjata B, Vignaud A, Zhang F, et al. Preclinical Development of a Lentiviral Vector for Gene Therapy of X-Linked Severe Combined Immunodeficiency. *Mol Ther Methods Clin Dev* (2018) 9:2367–59. doi: 10.1016/j.omtm.2018.03.002

18. Schena F, Penco F, Volpi S, Pastirionio C, Caorsi R, Kalli F, et al. Dye retardation in B-Cell Responses and T Follicular Helper Cell Function in ADA2 Deficiency Patients. *Eur J Immunol* (2021) 51(1):206–19. doi: 10.1002/eji.2020048549

19. Wu Z, Gao S, Watanabe N, Batchu S, Kajiyaga S, Diamond C, et al. Single-Cell Profiling of T Lymphocytes in Deficiency of Adenosine Deaminase 2. *J Leukoc Biol* (2021) 111(2):301–12. doi: 10.1002/jlb.504109-1011

20. Watanabe N, Gao S, Wu Z, Batchu S, Kajiyaga S, Diamond C, et al. Analysis of Deficiency of Adenosine Deaminase 2 Pathogenesis Based on Single-Cell RNA Sequencing of Monocytes. *J Leukoc Biol* (2021) 110(3):409–24. doi: 10.1002/JLB.3H1020-119RR

21. Ehlers L, Meyts I. What a Difference ADA2 Maker: Insights Into the Pathophysiology of ADA2 Deficiency From Single-Cell RNA Sequencing of Monocytes. *J Leukoc Biol* (2021) 110(3):405–7. doi: 10.1002/JLB.5CE0421-186R

22. Coldej RM, Carney G, Wielgosz MM, Zhou S, Zhan J, Sorrentino BP, et al. Comparison of Insulators and Promoters for Expression of the Wiskott–Aldrich Syndrome Protein Using Lentiviral Vectors. *Hum Gene Ther Clin Dev* (2013) 24(2):77–85. doi: 10.1089/humc.2012.244

23. Dai R, Romito M, Rivers E, Turchiano G, Blattner G, Vetharoy W, et al. Targeted Gene Correction of Human Hematopoietic Stem Cells for the
Treatment of Wiskott - Aldrich Syndrome. *Nat Commun* (2020) 11(1):4034. doi: 10.1038/s41467-020-17626-2

35. Rai R, Thrasher AJ, Cavazza A. Gene Editing for the Treatment of Primary Immunodeficiency Diseases. *Hum Gene Ther* (2021) 32(1–2):43–51. doi: 10.1089/hum.2020.185

36. Pavel-Dinu M, Wiebking V, Dejene BT, Srifa W, Mantri S, Nicolas CE, et al. Gene Correction for SCID-X1 in Long-Term Hematopoietic Stem Cells. *Nat Commun* (2019) 10(1):1634. doi: 10.1038/s41467-019-09614-y

37. Houghton BC, Booth C, Thrasher AJ. Lentivirus Technologies for Modulation of the Immune System. *Curr Opin Pharmacol* (2015) 24:119–27. doi: 10.1016/j.coph.2015.08.007

**Conflict of Interest:** PB has received institutional grants from: Novartis, SOBI, Roche, Chemocentryx, and Novimmune; consultancy fees from Roche, Novartis and SOBI; and speaker fees from UCB. DE received institutional grants from Lilly, Sobi, Roche and Pfizer. All research at Great Ormond Street Hospital NHS Foundation Trust and UCL Great Ormond Street Institute of Child Health is made possible by the NIHR Great Ormond Street Hospital Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Hong, Casimir, Houghton, Zhang, Jensen, Omorejimi, Torrance, Papadopoulou, Cummins, Roderick, Thrasher, Brogan and Eleftheriou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.